Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ACTRN12616001375448
ACTRN12616001375448TerminatedPhase 1

A Phase 1b Study Evaluating the Safety and Tolerability of GS-5801 in Patients with Chronic Hepatitis B

Gilead Sciences, Inc.0 sites60 target enrollmentStarted: October 5, 2016Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Terminated
Enrollment
60
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Treatment
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 65 Years (—)
Sex
All

Inclusion Criteria

  • •1. Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures
  • •2. Adult male and non-pregnant, non-lactating female subjects, (lactating females must agree to discontinue nursing before the study drug is administered and through the follow up period), 18 - 65 years of age inclusive based on the date of the Screening visit
  • •3. A negative serum pregnancy test is required for female subjects (unless surgically sterile or greater than two years postmenopausal).
  • •4. Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception.
  • •5. Documented evidence of chronic HBV infection (e.g. HBsAg positive for more than 6 months) with detectable HBsAg levels at Screening
  • •6. Have been on approved HBV OAV treatment for =>1 year prior to Screening, with HBV DNA below LLOQ (measured at least once) 6 or more months prior to Screening, and HBV DNA < 20 IU/mL at Screening
  • •7. Subjects currently taking Tenofovir DF, Tenofovir alafenamide, entecavir, adefovir, lamivudine, or telbivudine, either as single agent or in combination with no change in regimen for 3 months prior to screening.
  • •8. Screening ECG without clinically significant abnormalities and with QTcF interval (QT corrected using Fridericia’s formula) =<450 msec for males and =<470 msec for females
  • •9. Body mass index (BMI) 18-34 kg/m2, inclusive
  • •10. Must be willing and able to comply with all study requirements

Exclusion Criteria

  • •1. Extensive bridging fibrosis or cirrhosis as defined clinically, by imaging or by the following:
  • •a. Metavir => 3 or Ishak fibrosis score => 4 by a liver biopsy within 5 years of Screening, or, in the absence of an appropriate liver biopsy, either
  • •b. Screening FibroTest score of > 0.48 and APRI > 1, or
  • •c. Historic FibroScan with a result > 9 kPa within =< 6 months of screening (if available)
  • •If liver biopsy is available, the liver biopsy result supersedes (b)(and/or c, if available).
  • •If an appropriate liver biopsy is not available, fibrosis will be evaluated by (b) (and/or c, if available). In the event of discordance between (b) and (c), the FibroScan results will take precedence.
  • •2. Subjects meeting any of the following laboratory parameters at Screening:
  • •a. Hemoglobin <12 g/dL (for males), <11 g/dL (for females)
  • •b. White Blood cell count < 2500 IU/mL
  • •c. ALT > 3x ULN
  • •d. Direct bilirubin > 1.5x ULN
  • •e. INR > ULN unless the subject is stable on an anticoagulant regimen affecting INR
  • •f. Albumin < 3.9 g/dL
  • •g. Platelet Count < 125,000 /mL
  • •h. Estimate creatinine clearance (CLcr) < 80 mL/min (using the Cockcroft-Gault method based on serum creatinine and actual body weight as measured at the Screening evaluation)
  • •3. Co-infection with HIV, hepatitis C virus (HCV) or hepatitis D virus (HDV)
  • •4. Evidence of hepatocellular carcinoma (e.g. as evidenced by recent imaging)
  • •5. Malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g. basal cell skin cancer). Subjects under evaluation for possible malignancy are not eligible
  • •6. Significant cardiovascular, pulmonary, or neurological disease
  • •7. Diagnosis of autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, psoriasis of greater than mild severity), poorly controlled diabetes mellitus, significant psychiatric illness, severe chronic obstructive pulmonary disease (COPD), malignancy (with exception of certain skin cancers) hemoglobinopathy, retinal disease, or are immunosuppressed
  • •8. Chronic liver disease of a non-HBV etiology (e.g. hemochromatosis, Wilson’s disease, alpha-1 antitrypsin deficiency, cholangitis)
  • •9. Received solid organ or bone marrow transplant
  • •10. Received prolonged therapy with immunomodulators (e.g. corticosteroids) or biologics (e.g. monoclonal antibody, interferon) within 3 months of Screening
  • •11. Use of another investigational agents within 30 days of Screening, unless allowed by the Sponsor
  • •12. Current alcohol or substance abuse judged by the investigator to potentially interfere with subject compliance
  • •13. Known hypersensitivity to study drug, metabolites or formulation excipients
  • •14. Women who may wish to become pregnant during the course of the study
  • •15. Male subjects unwilling to refrain from sperm donation for at least 90 days after the last dose of study drug
  • •16. Use of any prohibited concomitant -medications
  • •17. Believed by the Study Investigator to be inappropriate for study

Investigators

Similar Trials

Completed
Phase 1
A Phase 1 Study to Evaluate the Safety of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy VolunteersHealthy to overweight subjects with undesirable subcutaneous fat thickness in bellySkin - Dermatological conditionsDiet and Nutrition - Obesity
ACTRN12618000868280Caliway Biopharmaceuticals Australia Pty Ltd40
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid TumorsMerkel cell carcinomaAdvanced Solid TumorsEndometrial cancerCancer - Lung - Non small cellCancer - Head and neckCancer - KidneyCancer - BreastCancer - Bowel - Back passage (rectum) or large bowel (colon)Cancer - ProstateCancer - BladderCancer - Ovarian and primary peritonealCancer - Oesophageal (gullet)Cancer - Malignant melanoma
ACTRN12617001641381Arcus Biosciences, Inc.39
Recruiting
Phase 1
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
JPRN-jRCT2031230438ozaki Akira30
Completed
Not Applicable
A Phase 1 Study to Evaluate the Safety and Tolerability of BYON5667 Eye Drops in Healthy Subjectsocular side effects with ADCs10015919
NL-OMON50780Byondis B.V.32
Active, not recruiting
Phase 1
A phase 1 study to evaluate GS-5829 alone and in combination with enzalutamide in patients with metastatic castrate-resistant prostate cancer.
EUCTR2015-003741-26-BEGilead Sciences, Inc.132
A Phase 1b Study Evaluating the Safety and... | Clinical Trial